[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100650076":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":24,"centralContacts":29,"locations":24,"responsibleParty":35,"collaborators":24,"id":37,"slug":38,"hasResults":39,"nctId":40,"briefTitle":41,"officialTitle":42,"acronym":24,"eligibilityCriteria":43,"healthyVolunteers":39,"sex":44,"minAge":45,"maxAge":24,"enrollmentInfo":46,"targetDuration":24,"studyType":49,"phases":50,"briefSummary":52,"conditions":53,"keywords":24,"overallStatus":55,"whyStopped":24,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":24},{"fullName":5,"class":6},"Nanchong Central Hospital","OTHER_GOV",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Standard Routine Therapy + 14-day Short-term Spinal Cord Stimulation","EXPERIMENTAL","Patients received stSCS in addition to standard routine therapy",[13],"Procedure: Standard Routine Therapy + 14-day Short-term Spinal Cord Stimulation",{"label":15,"type":10,"description":16,"interventionNames":17},"Standardized Routine Diabetic Foot Therapy","Patients receive standardized routine treatment for diabetic foot",[18],"Drug: Standardized Routine Diabetic Foot Therapy",[20,25],{"type":21,"name":15,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","No spinal cord stimulation intervention; unified comprehensive clinical management throughout follow-up:\n\n1. Precise glycemic control: Adjustment of oral hypoglycemic agents or insulin, regular HbA1c monitoring;\n2. Basic medication: Neurotrophic agents, lower limb microcirculation improvers, stepwise multi-modal analgesics;\n3. Standardized wound care: Debridement, dressing change and foot decompression;\n4. Health education: Diabetic diet guidance, foot self-care training and individualized exercise advice;\n5. Unified follow-up visits at 14 days, 1 month, 3 months and 6 months for indicator detection and adverse event documentation.",[15],null,{"type":26,"name":9,"description":27,"armGroupLabels":28,"otherNames":24},"PROCEDURE","All routine management identical to the control group, with additional 14-day reversible epidural SCS intervention:\n\n1. Epidural electrode implantation targeting T10-T12 spinal segments under local anesthesia;\n2. Standardized stimulation parameters set in accordance with domestic clinical guidelines for spinal cord stimulation; electrodes retained for 14 days and removed after the intervention period;\n3. Identical follow-up schedule and assessment indicators as the control group.",[9],[30],{"name":31,"role":32,"phone":33,"phoneExt":24,"email":34},"Zhenguo Gao","CONTACT","+8618404999336","gaozhenguo0822@163.com",{"type":36,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100650076","short-term-scs-for-refractory-diabetic-foot-neuropathic-pain-100650076",false,"NCT07740707","Short-term SCS for Refractory Diabetic Foot Neuropathic Pain","A Prospective Randomized Controlled Study on 14-day Short-term Spinal Cord Stimulation Minimally Invasive Intervention for Patients With Refractory Diabetic Foot Neuropathic Pain","Inclusion Criteria:\n\n1. Age ≥18 years;\n2. Confirmed type 2 diabetes mellitus, Wagner grade 1-3 diabetic foot;\n3. Persistent moderate-to-severe neuropathic pain (Numeric Rating Scale, NRS ≥4) after ≥3 months of standardized conservative treatment including glycemic control, neurotrophic drugs, multi-modal analgesia and wound care;\n4. Contraindications to lower extremity revascularization surgery, persistent pain after revascularization, or voluntary refusal of vascular surgery;\n5. Clear consciousness, capable of completing scale assessments and multi-timepoint follow-up;\n6. Voluntary participation with signed written informed consent.\n\nExclusion Criteria:\n\n1. Spinal deformity, spinal infection, intraspinal tumor or history of spinal surgery, precluding epidural electrode implantation;\n2. Severe coagulation disorders, systemic infection or uncontrolled severe active foot infection;\n3. Severe dysfunction of heart, liver, kidney or respiratory system, unable to tolerate minimally invasive operation;\n4. Previous spinal cord stimulation or peripheral nerve destructive surgery;\n5. Psychiatric disorders interfering with assessment and follow-up cooperation;\n6. Pregnant or lactating women;\n7. Concurrent enrollment in other clinical trials targeting diabetic foot or chronic pain interventions.","ALL","18 Years",{"count":47,"type":48},88,"ESTIMATED","INTERVENTIONAL",[51],"NA","This single-center, assessor-blinded randomized controlled trial enrolls 88 patients with drug-refractory diabetic foot neuropathic pain unsuitable for revascularization surgery. Participants are randomized 1:1 to receive standard diabetic foot care alone (control) or standard care plus 14-day short-term spinal cord stimulation (intervention). The primary outcome is pain remission rate at 6 months, with repeated assessments of microcirculation, nerve function, quality of life and adverse events over 6 months. This study evaluates the efficacy and safety of short-term spinal cord stimulation and develops standardized clinical protocols for this minimally invasive therapy.",[54],"Refractory Diabetic Foot Neuropathic Pain","NOT_YET_RECRUITING","2026-07-26",{"date":58,"type":59},"2026-08-03","ACTUAL",{"date":61,"type":48},"2026-08-01",{"date":63,"type":48},"2027-03-01",{"name":5,"class":6}]